» Articles » PMID: 8723744

Formation of (R)-8-hydroxywarfarin in Human Liver Microsomes. A New Metabolic Marker for the (S)-mephenytoin Hydroxylase, P4502C19

Overview
Specialty Pharmacology
Date 1996 May 1
PMID 8723744
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Kinetic studies demonstrate that two forms of human liver cytochrome P450 are responsible for the formation of (R)-8-hydroxywarfarin: a low-affinity enzyme (KM approximately 1.5 mM), previously identified as P4501A2; and a high-affinity enzyme (KM = 330 microM), now identified as P4502C19 on the basis of the following evidence. In crossover inhibition studies with P4501A2-depleted human liver microsomes between (R)-warfarin and (S)-mephenytoin, reciprocal competitive inhibition was observed. Apparent KM values for (S)-mephenytoin-4'-hydroxylation (52-67 microM) were similar to the determined Ki values (58-62 microM) for (S)-mephenytoin inhibition of (R)-8-hydroxywarfarin formation. Similarly, the apparent KM for (R)-warfarin 8-hydroxylation in furafylline-pretreated microsomes (KM = 289-395 microM) was comparable with the Ki values (280-360 microM) for (R)-warfarin inhibition of (S)-4'-hydroxymephenytoin formation. Inhibition studies with tranylcypromine, a known inhibitor of (S)-mephenytoin hydroxylase activity, and either substrate in three different microsomal preparations yielded nearly identical inhibitory constants: Ki = 8.7 +/- 1.6 microM for inhibition of (S)-4'-hydroxymephenytoin formation and 8.8 +/- 2.5 microM for inhibition of (R)-8-hydroxywarfarin formation. In addition, fluconazole, a potent inhibitor of (R)-warfarin 8-hydroxylation, Ki = 2 microM, was found to inhibit (S)-mephenytoin hydroxylation with an identical Ki (2 microM). Finally, a strong correlation between (S)-mephenytoin 4-hydroxylation and (R)-warfarin 8-hydroxylation activities in furafylline-pretreated microsomes was demonstrated in 14 human liver microsomal preparations (r2 = 0.97).

Citing Articles

Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery.

Liu Z, Luo F, Zhao J, Chen W, Gao W, Zhou Z Pharmacol Rep. 2024; 76(2):390-399.

PMID: 38457019 DOI: 10.1007/s43440-024-00575-8.


Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.

Marie S, Frost K, Hau R, Martinez-Guerrero L, Izu J, Myers C Acta Pharm Sin B. 2023; 13(1):1-28.

PMID: 36815037 PMC: 9939324. DOI: 10.1016/j.apsb.2022.08.018.


Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD).

Nasrin S, Coates S, Bardhi K, Watson C, Muscat J, Lazarus P Chem Res Toxicol. 2023; 36(2):177-187.

PMID: 36626330 PMC: 9945182. DOI: 10.1021/acs.chemrestox.2c00259.


Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling.

Yeung C, Beers J, Jackson K, Edginton A CPT Pharmacometrics Syst Pharmacol. 2022; 12(3):320-332.

PMID: 36540909 PMC: 10014054. DOI: 10.1002/psp4.12908.


.

Cheng S, Flora D, Rettie A, Brundage R, Tracy T Drug Metab Dispos. 2022; 50(9).

PMID: 35798368 PMC: 9488977. DOI: 10.1124/dmd.122.000877.